



## **Xellia Pharmaceuticals Joins End Drug Shortages Alliance**

**Copenhagen, Denmark and Buffalo Grove, IL, USA - 16 December 2022**– Xellia Pharmaceuticals announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.

“We are very proud to join as member of End Drug Shortages Alliance, and be part of this important collaboration, where we can, alongside other key industry stakeholders engage in strategic discussion, and knowledge share on how to best tackle the national concern of drug shortages.

Security of supply, and consistency in supply of our critical medicines used to treat often life-threatening conditions is a key aspect of our commitments as an organization. Through our global vertically integrated supply chain, we continuously work to improve supply security through multiple sources of in-house production of our APIs and drug products. We hold great focus on accessibility of our products to patients in need, and in the importance of local production.

Thereby joining the Alliance which holds a common mission and goal to ours makes a natural fit. We sincerely look forward to working together with colleagues across other organizations to participate in creating national solutions.” said Peter Baker, Chief Commercial Officer North America, Xellia Pharmaceuticals USA LLC.

The End Drug Shortages Alliance was launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders and champions. Efforts will focus on improving access to medications through greater transparency across market participants, leading to improved quality manufacturing of medications and production of additional supply.

"We are grateful to have Xellia Pharmaceuticals join the alliance to end drug shortages," said Eric Tichy, division chair of pharmacy supply solutions for Mayo Clinic, who serves as the Chair for the Alliance advisory board. "Collaboration among organizations strengthens our ability to improve the quality of life for patients that rely on these medications. Together, we can make a difference."

Learn more at [www.EndDrugShortages.com](http://www.EndDrugShortages.com).

ENDS

### **About End Drug Shortages Alliance**

The End Drugs Shortages Alliance is a collaboration of select health systems, supply chain, industry and other stakeholders including group purchasing organizations, manufacturers, distributors and other industry thought leaders dedicated to solving the pharmaceutical supply challenges that disrupt access to essential medications in the U.S. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve undisrupted access to essential medications for health care providers and patients.



## **About Xellia Pharmaceuticals**

Xellia Pharmaceuticals is a specialty pharmaceutical company providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. The Company has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms, where the majority are injectable drug products.

Committed to providing security and consistency in supply of critical care therapies, Xellia holds a global vertically integrated supply chain, where the Company continuously works to deliver on this commitment through offering multiple sources of in-house production of its APIs and drug products, integrated with Xellia's R&D centers of excellence. Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East, and North America. Xellia Pharmaceuticals is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,700 people.